Avalo Therapeutics Inc (AVTX) - Total Liabilities

Latest as of September 2025: $33.55 Million USD

Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has total liabilities worth $33.55 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Avalo Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.

Avalo Therapeutics Inc - Total Liabilities Trend (2012–2024)

This chart illustrates how Avalo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Avalo Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Avalo Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Avalo Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Honey Hope Honesty Enterprise Co Ltd TWO:8043	Taiwan	NT$1.83 Billion
Balmer Lawrie & Company Limited NSE:BALMLAWRIE	India	Rs12.69 Billion
Public Policy Holding Company, Inc. Common Stock NASDAQ:PPHC	USA	$127.65 Million
Divgi Torqtransfer Systems Limited NSE:DIVGIITTS	India	Rs809.29 Million
Lime Technologies AB (publ) ST:LIME	Sweden	Skr556.23 Million
Chinese Maritime Transport Ltd TW:2612	Taiwan	NT$12.79 Billion
Oceania Healthcare Ltd AU:OCA	Australia	AU$1.88 Billion
Merlin, Inc. NASDAQ:MRLN	USA	$619.23 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Avalo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Avalo Therapeutics Inc market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	14.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.27	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Avalo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Avalo Therapeutics Inc (2012–2024)

The table below shows the annual total liabilities of Avalo Therapeutics Inc from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	$17.70 Million	+29.30%
2023-12-31	$13.69 Million	-69.09%
2022-12-31	$44.28 Million	-22.49%
2021-12-31	$57.13 Million	+197.67%
2020-12-31	$19.19 Million	+26.99%
2019-12-31	$15.11 Million	-69.37%
2018-12-31	$49.34 Million	+223.25%
2017-12-31	$15.26 Million	+174.44%
2016-12-31	$5.56 Million	-35.13%
2015-12-31	$8.57 Million	-77.81%
2014-12-31	$38.65 Million	+68.60%
2013-12-31	$22.92 Million	+1384.80%
2012-12-31	$1.54 Million	--

About Avalo Therapeutics Inc

NASDAQ:AVTX USA Biotechnology

Market Cap

$337.86 Million

Market Cap Rank

#14371 Global

#3408 in USA

Share Price

$18.25

Change (1 day)

-5.88%

52-Week Range

$8.20 - $22.87

All Time High

$20793.60